Cephalon Launches Takeover Bid For Australian Biotech Arana
This article was originally published in The Pink Sheet Daily
Executive Summary
Arana’s lead compound ART621 is a new-generation TNF alpha blocker in Phase II trials for rheumatoid arthritis and psoriasis.